Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Longitudinal Effects of Everolimus on White Matter Diffusion in Tuberous Sclerosis Complex.

Peters JM, Prohl A, Kapur K, Nath A, Scherrer B, Clancy S, Prabhu SP, Sahin M, Franz DN, Warfield SK, Krueger DA.

Pediatr Neurol. 2018 Oct 18. pii: S0887-8994(18)30926-3. doi: 10.1016/j.pediatrneurol.2018.10.005. [Epub ahead of print]

PMID:
30424962
2.

mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex.

Franz DN, Krueger DA.

Am J Med Genet C Semin Med Genet. 2018 Sep;178(3):365-373. doi: 10.1002/ajmg.c.31655. Epub 2018 Oct 11. Review.

PMID:
30307123
3.

Measuring Health-Related Quality of Life in Tuberous Sclerosis Complex - Psychometric Evaluation of Three Instruments in Individuals With Refractory Epilepsy.

de Vries PJ, Franz DN, Curatolo P, Nabbout R, Neary M, Herbst F, Sully K, Brohan E, Bennett B, Lawson JA.

Front Pharmacol. 2018 Aug 30;9:964. doi: 10.3389/fphar.2018.00964. eCollection 2018.

4.

Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial.

Curatolo P, Franz DN, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, de Vries PJ, Dlugos DJ, Fan J, Ridolfi A, Pelov D, Voi M, French JA.

Lancet Child Adolesc Health. 2018 Jul;2(7):495-504. doi: 10.1016/S2352-4642(18)30099-3. Epub 2018 May 24.

PMID:
30169322
5.

Thoracoabdominal imaging of tuberous sclerosis.

Morin CE, Morin NP, Franz DN, Krueger DA, Trout AT, Towbin AJ.

Pediatr Radiol. 2018 Aug;48(9):1307-1323. doi: 10.1007/s00247-018-4123-y. Epub 2018 Aug 4. Review.

PMID:
30078036
6.

Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2.

Bissler JJ, Budde K, Sauter M, Franz DN, Zonnenberg BA, Frost MD, Belousova E, Berkowitz N, Ridolfi A, Christopher Kingswood J.

Nephrol Dial Transplant. 2018 Jul 19. doi: 10.1093/ndt/gfy132. [Epub ahead of print]

PMID:
30053159
7.

Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience.

Krueger DA, Capal JK, Curatolo P, Devinsky O, Ess K, Tzadok M, Koenig MK, Narayanan V, Ramos F, Jozwiak S, de Vries P, Jansen AC, Wong M, Mowat D, Lawson J, Bruns S, Franz DN; TSCure Research Group.

Eur J Paediatr Neurol. 2018 Jul 4. pii: S1090-3798(17)31969-4. doi: 10.1016/j.ejpn.2018.06.007. [Epub ahead of print]

PMID:
30005812
8.

Calcification in cerebral parenchyma affects pharmacoresistant epilepsy in tuberous sclerosis.

Zhang MN, Zou LP, Wang YY, Pang LY, Ma SF, Huang LL, Gao Y, Lu Q, Franz DN.

Seizure. 2018 Aug;60:86-90. doi: 10.1016/j.seizure.2018.06.011. Epub 2018 Jun 15.

PMID:
29929111
9.

Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures.

Franz DN, Lawson JA, Yapici Z, Brandt C, Kohrman MH, Wong M, Milh M, Wiemer-Kruel A, Voi M, Coello N, Cheung W, Grosch K, French JA.

Epilepsia. 2018 Jun;59(6):1188-1197. doi: 10.1111/epi.14085. Epub 2018 May 4.

10.

Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies.

Franz DN, Budde K, Kingswood JC, Belousova E, Sparagana S, de Vries PJ, Berkowitz N, Ridolfi A, Bissler JJ.

J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1796-1803. doi: 10.1111/jdv.14964. Epub 2018 Jul 16.

PMID:
29569806
11.

Renal Lesions in Lymphangioleiomyomatosis and Tuberous Sclerosis Complex Are Rarely Biologically Aggressive.

Trout AT, Towbin AJ, Franz DN.

AJR Am J Roentgenol. 2018 Mar;210(3):W131. doi: 10.2214/AJR.17.18996. No abstract available.

PMID:
29469627
12.

Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders.

Krueger DA, Sadhwani A, Byars AW, de Vries PJ, Franz DN, Whittemore VH, Filip-Dhima R, Murray D, Kapur K, Sahin M.

Ann Clin Transl Neurol. 2017 Nov 12;4(12):877-887. doi: 10.1002/acn3.494. eCollection 2017 Dec.

13.

Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex.

Sparagana S, Franz DN, Krueger DA, Bissler JJ, Berkowitz N, Burock K, Kingswood JC.

PLoS One. 2017 Oct 12;12(10):e0186235. doi: 10.1371/journal.pone.0186235. eCollection 2017.

14.

The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.

Bissler JJ, Franz DN, Frost MD, Belousova E, Bebin EM, Sparagana S, Berkowitz N, Ridolfi A, Kingswood JC.

Pediatr Nephrol. 2018 Jan;33(1):101-109. doi: 10.1007/s00467-017-3806-1. Epub 2017 Oct 9.

15.

Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells.

Li C, Liu X, Liu Y, Zhang E, Medepalli K, Masuda K, Li N, Wikenheiser-Brokamp KA, Osterburg A, Borchers MT, Kopras EJ, Plas DR, Sun J, Franz DN, Capal JK, Mays M, Sun Y, Kwiatkowski DJ, Alayev A, Holz MK, Krueger DA, Siroky BJ, Yu JJ.

Mol Cancer Res. 2017 Oct;15(10):1318-1330. doi: 10.1158/1541-7786.MCR-17-0077. Epub 2017 Jul 14.

16.

Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor.

Siroky BJ, Towbin AJ, Trout AT, Schäfer H, Thamann AR, Agricola KD, Tudor C, Capal J, Dixon BP, Krueger DA, Franz DN.

J Pediatr. 2017 Aug;187:318-322.e2. doi: 10.1016/j.jpeds.2017.05.015. Epub 2017 Jun 7.

PMID:
28600153
17.

Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus.

Arroyo MS, Krueger DA, Broomall E, Stevenson CB, Franz DN.

Pediatr Neurol. 2017 Jul;72:81-85. doi: 10.1016/j.pediatrneurol.2017.04.008. Epub 2017 Apr 18.

PMID:
28511812
18.

GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects.

Platzer K, Yuan H, Schütz H, Winschel A, Chen W, Hu C, Kusumoto H, Heyne HO, Helbig KL, Tang S, Willing MC, Tinkle BT, Adams DJ, Depienne C, Keren B, Mignot C, Frengen E, Strømme P, Biskup S, Döcker D, Strom TM, Mefford HC, Myers CT, Muir AM, LaCroix A, Sadleir L, Scheffer IE, Brilstra E, van Haelst MM, van der Smagt JJ, Bok LA, Møller RS, Jensen UB, Millichap JJ, Berg AT, Goldberg EM, De Bie I, Fox S, Major P, Jones JR, Zackai EH, Abou Jamra R, Rolfs A, Leventer RJ, Lawson JA, Roscioli T, Jansen FE, Ranza E, Korff CM, Lehesjoki AE, Courage C, Linnankivi T, Smith DR, Stanley C, Mintz M, McKnight D, Decker A, Tan WH, Tarnopolsky MA, Brady LI, Wolff M, Dondit L, Pedro HF, Parisotto SE, Jones KL, Patel AD, Franz DN, Vanzo R, Marco E, Ranells JD, Di Donato N, Dobyns WB, Laube B, Traynelis SF, Lemke JR.

J Med Genet. 2017 Jul;54(7):460-470. doi: 10.1136/jmedgenet-2016-104509. Epub 2017 Apr 4.

19.
20.

Long-term treatment of epilepsy with everolimus in tuberous sclerosis.

Krueger DA, Wilfong AA, Mays M, Talley CM, Agricola K, Tudor C, Capal J, Holland-Bouley K, Franz DN.

Neurology. 2016 Dec 6;87(23):2408-2415. Epub 2016 Nov 4.

21.

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.

French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN.

Lancet. 2016 Oct 29;388(10056):2153-2163. doi: 10.1016/S0140-6736(16)31419-2. Epub 2016 Sep 6.

22.

Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy.

Capal JK, Franz DN.

Neuropsychiatr Dis Treat. 2016 Aug 25;12:2165-72. doi: 10.2147/NDT.S91248. eCollection 2016. Review.

23.

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost MD, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Niolat J, Jóźwiak S.

PLoS One. 2016 Jun 28;11(6):e0158476. doi: 10.1371/journal.pone.0158476. eCollection 2016.

24.

Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial.

Jóźwiak S, Kotulska K, Berkowitz N, Brechenmacher T, Franz DN.

J Pediatr. 2016 May;172:151-155.e1. doi: 10.1016/j.jpeds.2016.01.027. Epub 2016 Feb 6.

PMID:
26858193
25.

Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing.

Tyburczy ME, Dies KA, Glass J, Camposano S, Chekaluk Y, Thorner AR, Lin L, Krueger D, Franz DN, Thiele EA, Sahin M, Kwiatkowski DJ.

PLoS Genet. 2015 Nov 5;11(11):e1005637. doi: 10.1371/journal.pgen.1005637. eCollection 2015 Nov.

26.

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.

Franz DN, Agricola K, Mays M, Tudor C, Care MM, Holland-Bouley K, Berkowitz N, Miao S, Peyrard S, Krueger DA.

Ann Neurol. 2015 Dec;78(6):929-38. doi: 10.1002/ana.24523. Epub 2015 Nov 9.

27.

Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Anak O, Niolat J, Jozwiak S.

Lancet Oncol. 2014 Dec;15(13):1513-20. doi: 10.1016/S1470-2045(14)70489-9. Epub 2014 Nov 10.

PMID:
25456370
28.

Long-term outcomes of resective epilepsy surgery after invasive presurgical evaluation in children with tuberous sclerosis complex and bilateral multiple lesions.

Arya R, Tenney JR, Horn PS, Greiner HM, Holland KD, Leach JL, Gelfand MJ, Rozhkov L, Fujiwara H, Rose DF, Franz DN, Mangano FT.

J Neurosurg Pediatr. 2015 Jan;15(1):26-33. doi: 10.3171/2014.10.PEDS14107.

PMID:
25360852
29.

The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.

Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM, Korf BR, Flamini JR, Kohrman MH, Sparagana SP, Wu JY, Brechenmacher T, Stein K, Berkowitz N, Bissler JJ, Franz DN.

Nephrol Dial Transplant. 2014 Jun;29(6):1203-10. doi: 10.1093/ndt/gfu013. Epub 2014 Apr 11.

30.

Reply: To PMID 23798472.

Krueger D, Wilfong A, Franz DN.

Ann Neurol. 2014 Jan;75(1):164-5. doi: 10.1002/ana.24046. Epub 2014 Jan 2. No abstract available.

PMID:
24243553
32.

Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012.

Roth J, Roach ES, Bartels U, Jóźwiak S, Koenig MK, Weiner HL, Franz DN, Wang HZ.

Pediatr Neurol. 2013 Dec;49(6):439-44. doi: 10.1016/j.pediatrneurol.2013.08.017. Epub 2013 Oct 15.

33.

Stiripentol in Dravet syndrome: results of a retrospective U.S. study.

Wirrell EC, Laux L, Franz DN, Sullivan J, Saneto RP, Morse RP, Devinsky O, Chugani H, Hernandez A, Hamiwka L, Mikati MA, Valencia I, Le Guern ME, Chancharme L, de Menezes MS.

Epilepsia. 2013 Sep;54(9):1595-604. doi: 10.1111/epi.12303. Epub 2013 Jul 12.

34.

Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?

Wiegand G, May TW, Ostertag P, Boor R, Stephani U, Franz DN.

Eur J Paediatr Neurol. 2013 Nov;17(6):631-8. doi: 10.1016/j.ejpn.2013.06.002. Epub 2013 Jul 8.

PMID:
23845174
35.

Nursing implications for the lifelong management of tuberous sclerosis complex.

Agricola K, Tudor C, Krueger D, Franz DN.

J Neurosci Nurs. 2013 Aug;45(4):226-42. doi: 10.1097/JNN.0b013e3182986146. Review.

PMID:
23812052
36.

Everolimus treatment of refractory epilepsy in tuberous sclerosis complex.

Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN.

Ann Neurol. 2013 Nov;74(5):679-87. doi: 10.1002/ana.23960. Epub 2013 Sep 10.

PMID:
23798472
37.

Everolimus for astrocytomas in tuberous sclerosis - author's reply.

Franz DN.

Lancet. 2013 Apr 13;381(9874):1275. doi: 10.1016/S0140-6736(13)60837-5. No abstract available.

PMID:
23582393
38.

Lymphangioleiomyomatosis screening in women with tuberous sclerosis.

Cudzilo CJ, Szczesniak RD, Brody AS, Rattan MS, Krueger DA, Bissler JJ, Franz DN, McCormack FX, Young LR.

Chest. 2013 Aug;144(2):578-585. doi: 10.1378/chest.12-2813.

PMID:
23539171
39.

Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis.

Malinowska IA, Lee N, Kumar V, Thiele EA, Franz DN, Ashwal S, Sagalowsky A, Dimario FJ Jr, Cutler D, Krueger D, Camposano S, Paolini J, Dabora SL.

PLoS One. 2013;8(2):e56199. doi: 10.1371/journal.pone.0056199. Epub 2013 Feb 20.

40.

Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.

Krueger DA, Care MM, Agricola K, Tudor C, Mays M, Franz DN.

Neurology. 2013 Feb 5;80(6):574-80. doi: 10.1212/WNL.0b013e3182815428. Epub 2013 Jan 16.

41.

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S.

Lancet. 2013 Jan 12;381(9861):125-32. doi: 10.1016/S0140-6736(12)61134-9. Epub 2012 Nov 14. Erratum in: Lancet. 2013 Jan 12;381(9861):116.

PMID:
23158522
42.

Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.

Franz DN, Agricola KD, Tudor CA, Krueger DA.

J Child Neurol. 2013 May;28(5):602-7. doi: 10.1177/0883073812449904. Epub 2012 Jul 17.

PMID:
22805244
43.

Molecular therapies for tuberous sclerosis and neurofibromatosis.

Franz DN, Weiss BD.

Curr Neurol Neurosci Rep. 2012 Jun;12(3):294-301. doi: 10.1007/s11910-012-0269-4. Review.

PMID:
22544507
44.

Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome.

Tate ED, Pranzatelli MR, Verhulst SJ, Markwell SJ, Franz DN, Graf WD, Joseph SA, Khakoo YN, Lo WD, Mitchell WG, Sivaswamy L.

J Child Neurol. 2012 Jul;27(7):875-84. doi: 10.1177/0883073811428816. Epub 2012 Feb 28. Erratum in: J Child Neurol. 2012 Oct;27(10):1364. Dosage error in article text.

PMID:
22378659
45.

Vigabatrin for childhood partial-onset epilepsies.

Greiner HM, Lynch ER, Fordyce S, Agricola K, Tudor C, Franz DN, Krueger DA.

Pediatr Neurol. 2012 Feb;46(2):83-8. doi: 10.1016/j.pediatrneurol.2011.11.020.

PMID:
22264701
46.

Everolimus alters white matter diffusion in tuberous sclerosis complex.

Tillema JM, Leach JL, Krueger DA, Franz DN.

Neurology. 2012 Feb 21;78(8):526-31. doi: 10.1212/WNL.0b013e318247ca8d. Epub 2012 Jan 18.

PMID:
22262746
47.

Psychiatric comorbidity and treatment response in patients with tuberous sclerosis complex.

Chung TK, Lynch ER, Fiser CJ, Nelson DA, Agricola K, Tudor C, Franz DN, Krueger DA.

Ann Clin Psychiatry. 2011 Nov;23(4):263-9.

PMID:
22073383
48.

Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.

Franz DN.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1181-92. doi: 10.1586/era.11.93. Review.

PMID:
21916571
49.

Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease.

Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario FJ Jr, Miles D, Cutler D, Krueger D, Uppot RN, Rabenou R, Camposano S, Paolini J, Fennessy F, Lee N, Woodrum C, Manola J, Garber J, Thiele EA.

PLoS One. 2011;6(9):e23379. doi: 10.1371/journal.pone.0023379. Epub 2011 Sep 6.

50.

Regression of a cardiac rhabdomyoma in a patient receiving everolimus.

Tiberio D, Franz DN, Phillips JR.

Pediatrics. 2011 May;127(5):e1335-7. doi: 10.1542/peds.2010-2910. Epub 2011 Apr 4.

PMID:
21464184

Supplemental Content

Loading ...
Support Center